Bhandari Sunil, Naudeer Sarah
Department of Renal Medicine, Hull and East Yorkshire Hospitals NHS Trust, Hull Royal Infirmary and Hull York Medical School, Kingston upon Hull, UK.
J Eval Clin Pract. 2008 Dec;14(6):996-1001. doi: 10.1111/j.1365-2753.2007.00932.x.
The National Service Framework advocates correction of anaemia in patients with chronic kidney disease (CKD). Oral iron is insufficient, while intravenous (IV) supplementation replenishes and maintains iron stores. In Yorkshire numerous peripheral clinics exist to reduce travel for patients, but patients must travel to the main unit for IV iron therapy. Therefore an outpatient service in tandem with a routine clinic for administration of IV CosmoFer was created.
To evaluate the feasibility and benefits of IV iron therapy in the outpatient clinic during active patient review for CKD patients.
A cross-sectional study of patients attending for total dose IV iron (n = 57) at a peripheral clinic. Iron was administered and monitored according to protocol by one of the clinic nurses with medical staff available in the adjoining room. Haemoglobin, ferritin and renal function were recorded pre-infusion and after 4-6 months. Results are given as medians/means +/- standard error.
A total of 76 IV infusions were carried out with no reported side effects or haemodynamic instability. Haemoglobin (median 10.9 vs. 11.3 g dL(-1), P = NS), creatinine and estimated glomerular filtration rate (eGFR) over the 6-month period remained stable. Serum ferritin rose significantly [80.9 +/- 6.2 vs. 186.4 +/- 18.2 g L(-1) (P < 0.001)]. Hospital time saved 380 day case bed hours, doctor hours saved 76 hours, and patient hours saved 3 hours/patient. Cost savings for TDI CosmoFer in peripheral clinic versus in centre therapy and versus sucrose, respectively, for 76 treatments was pound 5749.40 and pound 46,320.80 respectively.
We have demonstrated, in a resource-limited service, the feasibility and cost-effectiveness of a management care pathway for patients with CKD, in a peripheral clinic, to receive total dose IV CosmoFer without disruption of a functioning renal clinic.
国家服务框架提倡纠正慢性肾脏病(CKD)患者的贫血状况。口服铁剂效果不佳,而静脉补铁可补充并维持铁储备。在约克郡,有众多周边诊所,以减少患者的出行距离,但患者必须前往主院区接受静脉铁剂治疗。因此,我们设立了一项与常规门诊相结合的门诊服务,用于静脉注射科莫非(CosmoFer)。
评估在对CKD患者进行积极复诊期间,于门诊进行静脉铁剂治疗的可行性和益处。
一项针对在周边诊所接受全剂量静脉铁剂治疗的患者(n = 57)的横断面研究。铁剂由一名门诊护士按照方案进行给药和监测,旁边房间有医务人员随时待命。在输液前以及4 - 6个月后记录血红蛋白、铁蛋白和肾功能。结果以中位数/均值±标准误表示。
共进行了76次静脉输液,未报告有副作用或血流动力学不稳定情况。在6个月期间,血红蛋白(中位数10.9 vs. 11.3 g/dL(-1),P = 无显著差异)、肌酐和估算肾小球滤过率(eGFR)保持稳定。血清铁蛋白显著升高[80.9 ± 6.2 vs. 186.4 ± 18.2 μg/L(P < 0.001)]。节省住院时间380个日间病床小时,节省医生工作时间76小时,节省患者时间3小时/患者。对于76次治疗,在周边诊所使用科莫非进行全剂量静脉铁剂治疗与在中心治疗以及使用蔗糖相比,分别节省费用5749.40英镑和46320.80英镑。
我们已经证明,在资源有限的服务中,为CKD患者建立的一种管理护理途径具有可行性和成本效益,即在周边诊所接受全剂量静脉注射科莫非,而不影响肾脏门诊的正常运作。